Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells
Summary
Today at the 6th Annual Congress of the Perinatal Stem Cell Society in Salt Lake City, Utah, Director Sherley will address what he thinks is the second cause of slow adoption of the company’s initial technology. “Our tech is an amazing advance for the stem cell industry, but it takes a lot of time to do – previously several weeks to get an answer – even though an answer available nowhere else; and its rather expensive compared to other tests that confound the marketplace.” In his talk today, Sherley says, “Now, …everything will change.” Using its computational strength, Asymmetrex has discovered mathematical algorithms that allow simple cell count data from a few days of culture to be used to calculate the stem cell-specific count of a sample. Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development.